Getty Images
The "Santa Claus rally" was back on Wednesday, albeit with little conviction and limited breadth.
Another tame day for the broader indexes shifted the spotlight to individual equities, and interestingly, two very different companies' price moves were tethered to South Korean tech giant Samsung.
Biogen (BIIB, +9.5%) shares popped after the Korean Economic Daily, citing investment banking sources, reported that Samsung is in talks to buy the biotechnology firm for $42 billion – which would be its largest-ever transaction.
Also Wednesday, computer-memory maker Micron (MU, +3.5%) enjoyed a decent stock pop after reports that a COVID outbreak in a Chinese factory had forced Samsung – a major rival – to throttle back some production.
The broader market continues to be driven by cautious optimism that the omicron COVID variant's effect on equities will ultimately be modest.
"Viruses tend to get more contagious and less deadly as they evolve; we believe this is happening to the COVID virus," says Paul Zemsky, chief investment officer of multi-asset strategies and solutions at Voya Investment Management. "Markets have determined that Omicron won't have a long-lasting, negative impact on the economy, and therefore won't cause a big sell-off."
Sign up for Kiplinger's FREE Investing Weekly e-letter for stock, ETF and mutual fund recommendations, and other investing advice.
The S&P 500 (+0.1% to 4,793) managed to scratch out its 70th consecutive new high of the year, while the Dow Jones Industrial Average (+0.3% to 36,488) extended its win streak to six sessions. However, the Nasdaq Composite (-0.1% to 15,766) slid for the second straight day.
YCharts
Other news in the stock market today:
2022 will be chock full of attractive investment opportunities, but metaphorically speaking, you might do better with a squirt gun than with a water balloon.
Morgan Stanley is among the more bearish outfits with regards to 2022, saying that "with financial conditions tightening and earnings growth slowing, the 12-month risk/reward for the broad indices looks unattractive at current prices." But they add that "strong nominal GDP growth should continue to provide plenty of good investment opportunities at the stock level for active managers."
We at Kiplinger have already weighed in plenty over the past few months, offering up our best stock ideas for 2022, as well as a long list of value plays for what many predict will be a value-friendly environment. So today, we'll share with you what Wall Street's pros have to say.
Our list of the pros' 22 top stocks to invest in for 2022 is a diverse group of holdings covering most of the 11 sectors – understandable given that analysts aren't exactly unanimous about where the market's gains will come from. Each of these picks enjoys a Strong Buy consensus rating among the covering analysts who have sounded off on these stocks over the past three months.
Check out the link above to discover what these high-conviction picks are, and what about them has Wall Street so excited.
Kiplinger is part of Future plc, an international media group and leading digital publisher. Visit our corporate site www.futurenet.com
© Future US LLC, 10th floor, 1100 13th Street, N.W Washington, DC 20005 . All rights reserved.
